Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells

Gener, P. ; Montero, S. ; Xandri-Monje, H. ; Díaz-Riascos, Z.V. ; Rafael, D. ; Andrade, F. ; Martínez-Trucharte, F. ; González, P. ; Seras-Franzoso, J. ; Manzano, A. ; Arango, D. ; Sayós, J. ; Abasolo, I. ; Schwartz, S.Jr

Resumen: Tumor recurrence, metastatic spread and progressive gain of chemo-resistance of advanced cancers are sustained by the presence of cancer stem cells (CSCs) within the tumor. Targeted therapies with the aim to eradicate these cells are thus highly regarded. However, often the use of new anti-cancer therapies is hampered by pharmacokinetic demands. Drug delivery through nanoparticles has great potential to increase efficacy and reduce toxicity and adverse effects. However, its production has to be based on intelligent design. Likewise, we developed polymeric nanoparticles loaded with Zileuton™, a potent inhibitor of cancer stem cells (CSCs), which was chosen based on high throughput screening. Its great potential for CSCs treatment was subsequently demonstrated in in vitro and in in vivo CSC fluorescent models. Encapsulated Zileuton™ reduces amount of CSCs within the tumor and effectively blocks the circulating tumor cells (CTCs) in the blood stream and metastatic spread.

Idioma: Inglés

DOI: 10.1016/j.nano.2019.102106

Año: 2020

Publicado en: Nanomedicine: Nanotechnology, Biology, and Medicine 24 (2020), 102106 [13 pp]
ISSN: 1549-9634

Factor impacto JCR: 6.458 (2020)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 28 / 140 = 0.2 (2020) - Q1 - T1
Categ. JCR: NANOSCIENCE & NANOTECHNOLOGY rank: 36 / 106 = 0.34 (2020) - Q2 - T2

Factor impacto SCIMAGO: 1.262 - Bioengineering (Q1) - Biomedical Engineering (Q1) - Materials Science (miscellaneous) (Q1) - Pharmaceutical Science (Q1) - Molecular Medicine (Q1) - Nanoscience and Nanotechnology (Q1) - Medicine (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/FEDER-ISCIII/FIS-AC15-00092
Financiación: info:eu-repo/grantAgreement/ES/FEDER-ISCIII/FIS-PI14-02079
Financiación: info:eu-repo/grantAgreement/ES/FEDER-ISCIII/FIS-PI17-02242
Financiación: info:eu-repo/grantAgreement/EC/H2020/800983/EU/Evolvable platform for programmable nanoparticle-based cancer therapies/EVO-NANO

Tipo y forma: Artículo (Versión definitiva)